Dialysis patients get immune boost to fight COVID-19
NCT ID NCT04428008
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study tested a drug called thymalfasin (Ta1) to see if it could prevent COVID-19 infection in people with kidney failure who are on dialysis. These patients are at high risk because they spend time in dialysis centers and often have weak immune systems. The study involved 189 adults and measured how many got COVID-19, were hospitalized, or died.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Consultants
Kansas City, Kansas, 64111, United States
Conditions
Explore the condition pages connected to this study.